TARSUS PHARMACEUTICALS INC
(NASDAQ: TARS)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

36.250

+1.680 (+4.86%)
Range - - 37.160   (-%)
Open -
Previous Close 34.570
Bid Price 16.340
Bid Volume 9
Ask Price 16.900
Ask Volume 11
Volume 352,504
Value -
Remark
Delayed prices. Updated at 29 Mar 2024 01:29.
Data powered by
View All Events

Loading Chart...

Please login to view stock data and analysis